| Primary |
| Acute Myeloid Leukaemia |
42.9% |
| Myelodysplastic Syndrome |
34.1% |
| Mds |
3.6% |
| Myeloid Leukaemia |
3.4% |
| Chronic Myelomonocytic Leukaemia |
1.7% |
| Product Used For Unknown Indication |
1.7% |
| Acute Myeloid Leukaemia Recurrent |
1.5% |
| Colon Cancer Metastatic |
1.5% |
| Colorectal Cancer Metastatic |
1.5% |
| Infection Prophylaxis |
1.5% |
| Sarcoma |
1.5% |
| Rectal Cancer Metastatic |
1.0% |
| Acute Myelomonocytic Leukaemia |
0.7% |
| Colorectal Cancer |
0.7% |
| Neoplasm |
0.7% |
| Acute Myeloid Leukemia |
0.5% |
| Malignant Melanoma |
0.5% |
| Metastatic Malignant Melanoma |
0.5% |
| Salvage Therapy |
0.5% |
| Acute Myeloid Leukaemia |
0.2% |
|
| Pyrexia |
22.7% |
| Febrile Neutropenia |
9.9% |
| Thrombocytopenia |
8.5% |
| Haematotoxicity |
6.4% |
| Pneumonia |
6.4% |
| Infection |
5.0% |
| Respiratory Failure |
4.3% |
| White Blood Cell Count Decreased |
4.3% |
| Neutropenia |
3.5% |
| Sepsis |
3.5% |
| Septic Shock |
3.5% |
| Acute Myeloid Leukaemia |
2.8% |
| Bacterial Infection |
2.8% |
| Caecitis |
2.8% |
| Electrocardiogram Qt Prolonged |
2.8% |
| Anaemia |
2.1% |
| Anal Infection |
2.1% |
| Gastrointestinal Haemorrhage |
2.1% |
| Lung Infection |
2.1% |
| Off Label Use |
2.1% |
|
| Secondary |
| Myelodysplastic Syndrome |
33.5% |
| Stem Cell Transplant |
16.6% |
| Acute Myeloid Leukaemia |
14.4% |
| Prophylaxis Against Graft Versus Host Disease |
14.0% |
| Product Used For Unknown Indication |
7.7% |
| Drug Use For Unknown Indication |
3.1% |
| Infection Prophylaxis |
2.5% |
| Metastatic Malignant Melanoma |
1.8% |
| Acute Lymphocytic Leukaemia |
1.1% |
| Diffuse Large B-cell Lymphoma |
1.1% |
| Erythroleukaemia |
0.6% |
| Febrile Neutropenia |
0.5% |
| Thrombocytopenia |
0.5% |
| Acute Leukaemia |
0.4% |
| Bone Sarcoma |
0.4% |
| Colorectal Cancer |
0.4% |
| Pain |
0.4% |
| Paroxysmal Nocturnal Haemoglobinuria |
0.4% |
| Serum Ferritin Increased |
0.4% |
| Abdominal Pain Upper |
0.3% |
|
| Diarrhoea |
21.5% |
| Nausea |
7.6% |
| Chronic Graft Versus Host Disease |
7.0% |
| Thrombocytopenia |
7.0% |
| Mucosal Inflammation |
6.3% |
| White Blood Cell Count Decreased |
6.3% |
| Febrile Neutropenia |
4.4% |
| Sepsis |
4.4% |
| Multi-organ Failure |
3.8% |
| Staphylococcal Bacteraemia |
3.8% |
| Death |
3.2% |
| Pyrexia |
3.2% |
| Vomiting |
3.2% |
| Weight Decreased |
3.2% |
| Anaphylactic Reaction |
2.5% |
| Myelodysplastic Syndrome Transformation |
2.5% |
| Nervous System Disorder |
2.5% |
| Platelet Count Decreased |
2.5% |
| Weight Increased |
2.5% |
| White Blood Cell Count Increased |
2.5% |
|
| Concomitant |
| Product Used For Unknown Indication |
24.1% |
| Myelodysplastic Syndrome |
13.8% |
| Drug Use For Unknown Indication |
11.6% |
| Acute Myeloid Leukaemia |
9.9% |
| Prophylaxis |
5.6% |
| Iron Overload |
5.4% |
| Hypertension |
4.9% |
| Anaemia |
2.8% |
| Pain |
2.8% |
| Colon Cancer Metastatic |
2.4% |
| Haematopoietic Stem Cell Mobilisation |
2.4% |
| Idiopathic Thrombocytopenic Purpura |
1.9% |
| Thrombosis Prophylaxis |
1.9% |
| Dementia Alzheimer's Type |
1.7% |
| Paroxysmal Nocturnal Haemoglobinuria |
1.7% |
| Glaucoma |
1.5% |
| Insomnia |
1.5% |
| Plasma Cell Leukaemia |
1.5% |
| Refractory Anaemia With An Excess Of Blasts |
1.5% |
| Prophylaxis Against Graft Versus Host Disease |
1.3% |
|
| Febrile Neutropenia |
10.3% |
| Pancytopenia |
8.8% |
| Platelet Count Decreased |
8.8% |
| Vomiting |
8.8% |
| Acute Myeloid Leukaemia |
5.9% |
| Drug Ineffective |
5.9% |
| No Therapeutic Response |
5.9% |
| Death |
4.4% |
| Dyspnoea |
4.4% |
| Pneumonia |
4.4% |
| Prostate Cancer |
4.4% |
| Respiratory Failure |
4.4% |
| Chills |
2.9% |
| Emotional Distress |
2.9% |
| Gastrointestinal Haemorrhage |
2.9% |
| Hypotension |
2.9% |
| Mental Status Changes |
2.9% |
| Myelodysplastic Syndrome |
2.9% |
| Presyncope |
2.9% |
| Pyrexia |
2.9% |
|
